在英国一家急症医院对40毫克辛伐他汀的某些相互作用进行的回顾性观察研究。
A retrospective observational study of certain interactions with simvastatin 40 mg in an acute hospital in England.
作者信息
Boamah Danita, Bastian Liam, Wilcock Michael
机构信息
Trainee Pharmacist.
Lead Pharmacist for Digital Medicines.
出版信息
Br J Cardiol. 2024 May 14;31(2):020. doi: 10.5837/bjc.2024.020. eCollection 2024.
Abstract
The use of simvastatin 40 mg with various interacting medicines may lead to an increased risk of myopathy. We examined the extent to which hospital inpatients were prescribed simvastatin 40 mg with amiodarone, amlodipine, diltiazem, or verapamil, and assessed if any action was taken by prescribers or the pharmacy team to avoid this interaction. We found 56 patients on a combination of interest during their stay. Of the 20 (36%) patients not discharged on the combination, in six instances this was due to pharmacy intervention, while the remaining instances when simvastatin 40 mg or the interacting drug was amended or ceased were due to other clinical reasons. There is a need among clinicians and pharmacy teams within the hospital for recognition and management of these particular interactions.
摘要
辛伐他汀40毫克与多种相互作用药物联合使用可能会增加患肌病的风险。我们调查了住院患者中使用辛伐他汀40毫克与胺碘酮、氨氯地平、地尔硫䓬或维拉帕米联合用药的情况，并评估了开处方者或药房团队是否采取了任何措施来避免这种相互作用。我们发现有56名患者在住院期间使用了相关联合用药。在20名（36%）未以联合用药方式出院的患者中，有6例是由于药房干预，而其余辛伐他汀40毫克或相互作用药物被调整或停用的情况则是由于其他临床原因。医院的临床医生和药房团队需要认识并处理这些特定的相互作用。
相似文献
1
A retrospective observational study of certain interactions with simvastatin 40 mg in an acute hospital in England.在英国一家急症医院对40毫克辛伐他汀的某些相互作用进行的回顾性观察研究。
Br J Cardiol. 2024 May 14;31(2):020. doi: 10.5837/bjc.2024.020. eCollection 2024.
2
Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.评估同时接受强 P 糖蛋白抑制剂和他汀类药物治疗的患者的抗 Xa 活性。
J Clin Pharm Ther. 2022 May;47(5):668-675. doi: 10.1111/jcpt.13596. Epub 2022 Jan 15.
3
Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study.遵循药物标签建议以避免药物相互作用导致他汀类药物引起的肌病——一项全国登记研究。
PLoS One. 2013 Aug 6;8(8):e69545. doi: 10.1371/journal.pone.0069545. Print 2013.
4
Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.1,4-二氢吡啶类钙通道阻滞剂与他汀类药物之间的药代动力学药物相互作用：决定相互作用强度的因素及相关临床风险管理
Ther Clin Risk Manag. 2014;10:17-26. doi: 10.2147/TCRM.S55512. Epub 2013 Dec 20.
5
Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.辛伐他汀或阿托伐他汀与CYP3A4抑制剂相互作用的风险管理。
Drug Saf. 2008;31(7):587-96. doi: 10.2165/00002018-200831070-00004.
6
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.沙格列汀与细胞色素P450底物或抑制剂之间的双向药代动力学相互作用研究：辛伐他汀、缓释地尔硫䓬和酮康唑。
Clin Pharmacol. 2011;3:13-25. doi: 10.2147/CPAA.S15227. Epub 2011 Jun 22.
7
Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.一家退伍军人事务医疗中心针对同时接受胺碘酮和辛伐他汀治疗的患者开展的安全倡议结果。
J Manag Care Pharm. 2010 Sep;16(7):472-81. doi: 10.18553/jmcp.2010.16.7.472.
8
Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.在英国初级保健人群中，他汀类药物与细胞色素 P450 3A4 抑制剂联合使用。
Pharmacoepidemiol Drug Saf. 2012 May;21(5):485-93. doi: 10.1002/pds.2308. Epub 2012 Jan 12.
9
Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults.胺碘酮、维拉帕米或地尔硫䓬与直接口服抗凝剂联合使用及老年人出血风险
CJC Open. 2021 Nov 13;4(3):315-323. doi: 10.1016/j.cjco.2021.11.002. eCollection 2022 Mar.
10
Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.洛伐他汀和辛伐他汀药物相互作用的频率及临床相关性：一项观察性数据库研究
Drug Saf. 2008;31(3):231-40. doi: 10.2165/00002018-200831030-00004.
引用本文的文献
1
Early Surgery and Screw-Only Osteosyntheses in Minimally Invasive Treatment of Calcaneal Fractures-Risk or Benefit for Our Patients?早期手术及单纯螺钉内固定在跟骨骨折微创治疗中的应用——对我们的患者是风险还是益处？
J Clin Med. 2025 Jan 8;14(2):344. doi: 10.3390/jcm14020344.
本文引用的文献
1
Overall performance of a drug-drug interaction clinical decision support system: quantitative evaluation and end-user survey.药物相互作用临床决策支持系统的整体性能：定量评估和终端用户调查。
BMC Med Inform Decis Mak. 2022 Feb 22;22(1):48. doi: 10.1186/s12911-022-01783-z.
2
Prescription of suboptimal statin treatment regimens: a retrospective cohort study of trends and variation in English primary care.亚最佳他汀治疗方案的处方：一项关于英国初级医疗中趋势和差异的回顾性队列研究
Br J Gen Pract. 2020 Jul 30;70(697):e525-e533. doi: 10.3399/bjgp20X710873. Print 2020 Aug.
3
The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.澳大利亚社区居住老年人中临床相关CYP酶抑制剂与底物药物联合处方的流行情况。
J Clin Pharm Ther. 2014 Aug;39(4):383-9. doi: 10.1111/jcpt.12163. Epub 2014 Apr 7.
4
Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study.遵循药物标签建议以避免药物相互作用导致他汀类药物引起的肌病——一项全国登记研究。
PLoS One. 2013 Aug 6;8(8):e69545. doi: 10.1371/journal.pone.0069545. Print 2013.
5
Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.在英国初级保健人群中，他汀类药物与细胞色素 P450 3A4 抑制剂联合使用。
Pharmacoepidemiol Drug Saf. 2012 May;21(5):485-93. doi: 10.1002/pds.2308. Epub 2012 Jan 12.
6
Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases.在行政索赔和电子病历数据库中同时使用他汀类药物和 CYP3A4 抑制剂。
J Clin Lipidol. 2008 Dec;2(6):453-63. doi: 10.1016/j.jacl.2008.10.007. Epub 2008 Oct 28.
7
Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.新报销政策出台前后他汀类药物与CYP3A4抑制剂的联合用药情况。
Br J Clin Pharmacol. 2009 Feb;67(2):234-41. doi: 10.1111/j.1365-2125.2008.03345.x. Epub 2009 Feb 9.
8
Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.辛伐他汀或阿托伐他汀与CYP3A4抑制剂相互作用的风险管理。
Drug Saf. 2008;31(7):587-96. doi: 10.2165/00002018-200831070-00004.
9
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂的药代动力学和药效学改变：药物相互作用以及转运体和代谢酶功能的个体差异
Pharmacol Ther. 2006 Oct;112(1):71-105. doi: 10.1016/j.pharmthera.2006.03.003. Epub 2006 May 22.
Zotero 插件